Integrated Research on Acute Malnutrition in Chad

Wasting Clinical Trial

— IRAM-CHAD  

Official title:

Impact Evaluation of a Package of Integrated and Multisectoral Services (PASIM) to Reduce Child Wasting in Chad

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04867694
• Other study ID #: IRAM-TCHAD
• Status: Completed
• Phase: N/A
• Start date: May 3, 2021
• Est. completion date: May 31, 2022

Study information

• Verified date: February 2023
• Source: International Food Policy Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The IRAM Chad impact evaluation will be based on a cluster randomized controlled trial to study the impact of the integrated and multisectoral services package (PASIM), aimed at reducing the incidence and prevalence of wasting through integrated interventions, including, among other things, strengthening the activity of community care groups, food supplementation, water treatment, and screening for wasting conducted by families.

Description:

The general objective of the integrated and multisectoral services package (PASIM) is to reduce the incidence and prevalence of wasting through integrated interventions, including, among other things, strengthening the activity of community care groups. The members of the care groups conduct home visits to children aged 6-23 months (or up to 59 months when the children are under treatment for wasting or have been discharged in the previous 6 months) to deliver messages for behavioral change related to complementary feeding, health and hygiene ; deliver nutritional supplement and water purification inputs; improve screening coverage (training and supervision of families to take the Mid-Upper Arm Circumference measurements, referral of malnourished cases); and verify adherence to treatment of malnourished cases, in the health district of Mongo, Guéra province, Chad, Central Africa. The evaluation of the impact of PASIM will be based on a cluster randomized controlled trial, consisting of 100 villages or clusters of villages. The selected evaluation model will be that of a comparison of control groups (n=50; no implementation of the intervention) and intervention (n=50) through the follow-up of 3 cohorts : 1. Longitudinal in-home follow-up of a semi-open cohort of 1,750 children aged 6 months at enrollment (included continuously for 7 months and all followed through to the end of the study, which will last 9 months in total). 2. Longitudinal follow-up of all children aged 6-23 months enrolled for wasting treatment, based on health system records. 3. Longitudinal follow-up at home for 6 months of a closed cohort of 700 children aged 6-23 months at inclusion, discharged from a treatment for acute malnutrition. The primary impact results are as follows: - The longitudinal prevalence of wasting at the end of the study (Cohort 1). - The recovery rate (Cohort 2). - The incidence of relapse during the 11 months of the intervention (Cohort 3). Secondary impact results include, but are not limited to : - The incidence of wasting during the 11 months of the intervention (Cohort 1) ; - The screening coverage (cohorts 1 and 3); - The proportion of wasting cases enrolled in a treatment program (cohorts 1 and 3); - The adherence to treatment (cohort 2) during the 11 months of the intervention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2089
• Est. completion date: May 31, 2022
• Est. primary completion date: May 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 23 Months

Eligibility

Cohort 1 (home visits):

The criteria for inclusion of children in the main cohort are:

• 6-6.9 months of age
• Child singleton
• The mother must live in the study area from the time of inclusion.
• The consent of the mother or guardian

The exclusion criteria are :

• Congenital malformations that make anthropometric measurements impossible.
• Mother intends to leave the study area by December 2021. Cohort 2 (health registers-based):

The criteria for inclusion in the treatment cohort are :

• The child is included in a national treatment program.
• The child is between 6 and 23 months of age at inclusion
• Child lives in one of the 100 villages in the study area Cohort 3 (home visits):

The inclusion criteria for the relapse study are:

• Child has been successfully treated for wasting (moderate or severe) and has been discharged from the national treatment program within the last 30 days.
• The child is between 6 and 23 months of age at inclusion.
• The child is singleton.
• The mother must live in the study area from the time of inclusion.
• The consent of the mother or guardian

The exclusion criteria are :

• Congenital malformations that make anthropometric measurements impossible.
• Mother intends to leave the study area by December 2021.

Related Conditions & MeSH terms

• Cachexia
• Malnutrition
• Wasting

Intervention

Behavioral:
• BCC
Behavior change communication on Nutrition, Health & Hygiene, including (but not limited to) awareness of dietary diversification from 6 months of age and adequate complementary feeding; and raising awareness of good water and hygiene practices.

Dietary Supplement:
• Preventive supplement
Monthly delivery of a nutritional supplement: enriched flour (CSB++), at a dose of 3 kg/month/beneficiary child. The nutritional supplement is limited to [6-11] months old children diagnosed as non-wasted (green MUAC); or children [12-59] months old for 6 months after discharge from a CMAM treatment or consolidation program.
• MNP
Delivery of micronutrient powders to [12-23] months old children (30 sachets per month for 2 months, every 6 months, according to international recommendations).

Other:
• Water purification input
Monthly delivery of a water purification input: bleach or flocculant/decontamination sachets for the potabilization of the water of the whole household. The water treatment input is limited to households with [6-11] months old children, or children [12-59] months old enrolled in a CMAM treatment program and for 6 months after discharge.

Behavioral:
• Family MUAC
One-time delivery of a mid-upper arm circumference (MUAC) measuring tape and training of families in its use, and actions to be taken based on the results. This will involve distributing Shakir bands to all households with [6-59] months old children and training mothers/guardians, or any other family members who express an interest, in screening for wasting using the MUAC criteria, and explaining the procedure to follow if the child tests positive in the family. Formative supervision of MUAC measurement in families. The training will be carried out by the members of the care groups and at each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary.
• Screening by care group
Monthly screening by the care group volunteers of the children they follow, using the MUAC. Referral to the health center of [6-59] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled
• CMAM compliance
Weekly follow-up of [6-59] months old children under treatment and for 6 months after discharge from the national treatment and consolidation program : care group volunteers follow children under treatment until they recover and for the whole duration of their consolidation (for children cured of severe emaciation) through weekly home visits. They monitor treatment adherence (i.e., families follow the planned schedule of visits and receive inputs for treatment or consolidation) and treatment compliance (i.e., the malnourished or consolidating child receives the planned dose of therapeutic or supplementary food each day).

Locations

Country	Name	City	State
Chad	Mongo Health District	Mongo	Guera

Sponsors (4)

Lead Sponsor	Collaborator
International Food Policy Research Institute	Association Sahélienne de Recherches Appliquées pour le Développement Durable, ONG Moustagbal, UNICEF

Country where clinical trial is conducted

Chad, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Longitudinal prevalence of wasting among children enrolled at 6 months of age followed monthly until the end of the study (Cohort 1).	This indicator is defined for each child as the number of visits during which wasting is observed divided by the total number of monthly visits made (by interviewers).	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Primary	Recovery rate in children enrolled at [6-23] months of age for up to 3 months of treatment and followed through to discharge (Cohort 2).	This indicator is defined as the number of discharges considered cured according to national program criteria (WHZ>-2 and MUAC>=125mm and absence of bilateral edema for two consecutive visits, within 12 weeks of enrollment in the program) divided by the total number of exits recorded.	Up to 3 months, from date of inclusion in CMAM program until the date of recovery or 12th week after inclusion in CMAM program or date of death from any cause, whichever came first
Primary	Incidence of wasting in children enrolled at [6-23] months of age at discharge from a CMAM program cured, and followed for 6 months (Cohort 3).	This indicator is defined as the number of new cases of wasting recorded during monthly visits.	Up to 6 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Longitudinal prevalence of MAM (cohorts 1 & 3)	defined as the number of MAM diagnoses divided by the total number of monthly visits made	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Longitudinal prevalence of SAM (cohorts 1 & 3)	Defined as the number of SAM diagnoses divided by the total number of monthly visits made	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Incidence of wasting, MAM and SAM (cohort 1)	defined as the number of new cases of wasting, MAM and SAM recorded during monthly visits among children enrolled at 6 months of age followed monthly until the end of the study (Cohort 1).	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Incidence of MAM and SAM (cohort 3)	defined as the number of new cases of MAM and SAM recorded during monthly visits.	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	prevalence of anemia (cohorts 1 & 3)	Proportion of children with a hemoglobin level below 11g/dl	Up to 9 months, from date of enrolment until the date of last documented progression
Secondary	Mean hemoglobin concentration (cohorts 1 & 3)	Mean hemoglobin concentration measures by hemocue reader	Up to 9 months, from date of enrolment until the date of last documented progression
Secondary	Prevalence of stunting (cohorts 1 & 3)	proportion of children with HAZ <-2 (relative to the 2006 WHO reference)	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Height-for-age Z-score (cohorts 1 & 3)	Height-for-age Z-score relative to the 2006 WHO reference	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Longitudinal wasting screening coverage (cohorts 1 & 3)	defined as the proportion of children screened (using MUAC, weight-for-height or bilateral edema) in the month prior to the monthly visit. Two sub-outcomes will also be concerned: Screening coverage by care groups.; Coverage of the family MUAC component, which is the screening performed by a family member in the past month.	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Referral rate of positive screenings (cohorts 1 & 3)	defined as the proportion of children who tested positive during the month (according to the mother) and not under CMAM treatment who were referred to the health center or FARNE site.	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Enrollment of wasting, MAM, and SAM cases (cohorts 1 & 3)	proportion of cases who tested positive in the month prior to the monthly visit and not under CMAM treatment who were enrolled in a CMAM treatment program.	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Linear growth rate (cohorts 1 & 3)	change in height-for-age index per month	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Speed of weight growth (cohorts 1 & 3)	change in weight-for-height index per month	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Weight gain (cohorts 1 & 3)	weight change per month	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	MUAC gain (cohorts 1 & 3)	change in MUAC per month	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	longitudinal prevalence of childhood morbidity, i.e. acute respiratory infections, fever, diarrhea and malaria (cohorts 1 & 3)	the number of diagnoses of daily signs of these morbidities divided by the total number of days reported (1-3 per monthly visit made).	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Parental knowledge of nutrition, WASH, and health best practices (cohorts 1 & 3)	expressed as cumulative total and domain scores	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Longitudinal prevalence of minimum dietary diversity of infant and young children (cohorts 1 & 3)	the proportion of children who consumed at least 5 of the 8 food groups (including breast milk) the day before the survey.	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Longitudinal prevalence of Introduction of (semi) solid and soft complementary foods (cohorts 1 & 3)	the proportion of children 6-8 months of age who consumed (semi) solid and soft complementary foods the day before the survey Minimum dietary diversity in children, defined as the proportion of children who consumed at least 5 of the 8 food groups (including breast milk) the day before the survey.; Minimum meal frequency for children, defined as the proportion of children who had eaten the day before the survey: 2 meals for breastfed children 6-8 months, 3 meals for breastfed children 9-23 months, or 4 meals for non-breastfed children 6-23 months.; Minimum acceptable diet, defined as the proportion of children with both minimal dietary diversity and minimal meal frequency on the day before the survey.; Consumption of iron-rich or iron-fortified foods in children.	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Longitudinal prevalence of minimum meal frequency (cohorts 1 & 3)	the proportion of children who consumed the minimum recommended number of meals for their age on the day before the survey Minimum dietary diversity in children, defined as the proportion of children who consumed at least 5 of the 8 food groups (including breast milk) the day before the survey.; Minimum meal frequency for children, defined as the proportion of children who had eaten the day before the survey: 2 meals for breastfed children 6-8 months, 3 meals for breastfed children 9-23 months, or 4 meals for non-breastfed children 6-23 months.; Minimum acceptable diet, defined as the proportion of children with both minimal dietary diversity and minimal meal frequency on the day before the survey.; Consumption of iron-rich or iron-fortified foods in children.	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Practices related to water, hygiene and sanitation (cohorts 1 & 3)	Standard USAID indicators related to drinking water source, treatment, storage; hand washing; and sanitation	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	Vaccination coverage (cohorts 1 & 3)	Proportion of children with complete vaccination for their age	Up to 9 months, from date of enrolment until the date of last documented progression or date of death from any cause, whichever came first
Secondary	weight-for-height in z-score at enrollment in CMAM (cohort 2)	weight-for-height in z-score (relative to the 2006 WHO reference)	at the date of inclusion in CMAM program
Secondary	MUAC at enrollment in CMAM (cohort 2)	Mid-upper arm circumference (mm)	at the date of inclusion in CMAM program
Secondary	Duration of CMAM treatment (cohort 2)	defined as the number of days spent on treatment (enrollment and discharge) in children 6-23 months of age at enrollment, according to health registers	Up to 3 months, from date of inclusion in CMAM program until the date of recovery or 12th week after inclusion in CMAM program or date of death from any cause, whichever came first
Secondary	Treatment adherence (cohort 2)	defined as the proportion of cases enrolled for treatment who received timely treatment from dedicated services until recovery	Up to 3 months, from date of inclusion in CMAM program until the date of recovery or 12th week after inclusion in CMAM program or date of death from any cause, whichever came first
Secondary	Treatment outcomes (drop-out, death, transfer, non-response rates) (cohort 2)	Among proportion of cases enrolled for treatment	Up to 3 months, from date of inclusion in CMAM program until the date of recovery or 12th week after inclusion in CMAM program or date of death from any cause, whichever came first
Secondary	longitudinal prevalence of childhood morbidity (cohort 2)	defined by the number of days for which signs of these morbidities were reported divided by the total number of days observed/reported in the recall periods.	Up to 3 months, from date of inclusion in CMAM program until the date of recovery or 12th week after inclusion in CMAM program or date of death from any cause, whichever came first